Anemia Hemolytic Target Cell

**Target Cell Anemia** Hemolytic Target Cell Anemia (HCA) is a rare blood disorder associated with impaired red blood cell production. People suffering from ACM usually have small microcytes (the size of red blood cells) in their blood, which can lead to a lack of oxygen in the body.

In most cases, the cause of the disease is unknown and is hereditary, but sometimes it also develops after exposure to chemicals or genetic mutations. Most people with this disease do well in the early stages. However, as the disease progresses, it can get worse and cause severe complications, including shortness of breath, fatigue, dizziness and low blood pressure.

**Treatment of target anemia** in adults and children is the same in all countries. They only treat symptoms caused by a lack of oxygen. At the same time, the person’s condition and changes in the state of the red blood are monitored. Unfortunately, with target anemia, none of the drugs prescribed to treat most anemia can return the sick person to a normal life. And with or without it, people live limited lives. Treatment of the target is performed by transfusion of blood or red blood cells. Most often it is performed on one of the four blood types and injected into the red blood cells. Transfusion is carried out no more than once or twice a week. Taking iron supplements may be helpful if you have anemia. Iron supplements are necessary because they stimulate the formation of hemoglobin in erythroid cells, which carry out transport. Children with target anemia receive small amounts of essential foods and supplements. Adults with target deficiencies need large amounts of vitamin B12, folic acid, and iron. Everyone on treatment receives 600 to 800 mg/day (more in some cases) of iron for the first few weeks